Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2005

View Archived Issues

Schering AG plans additional phase III Crohn's disease trial for sargramostim

Phase IIa trials begin for melanoma vaccine CYT-004-MelQbG10

ABC2 and Genentech collaborate to study Avastin for GBM

Ranbaxy completes proof-of-concept for antimalarial RBx-11160

Orapred ODT filing accepted for review

Ark receives license to manufacture commercial supplies of gene-based medicine

Intercell aligns with CDC for development of Pneumococcus vaccine

New phase I study for Amplimexon plus docetaxel in cancer patients

Phase II study of Xanafide plus ara-C for secondary AML

Alinea announces Series A financing

Cardium Therapeutics and Aries Ventures to merge

Idera seeks to amend HYB-2055 phase II protocol

Viprovex studied as potential treatment for anthrax infection

Etomoxir reemerges as a potential antipsoriatic agent

Living Cell Technologies requests pre-IND meeting for NeurotrophinCell product

MedImmune and Avidia combine strengths to develop anticancer products

Repositioning study indicates utility of EVT-201 for insomnia

Approvable letter for Sparlon for ADHD

Levemir approved for use in children

New data on the immunomodulatory effects of FTY-720

SP-600125 evokes suppression of primary T-cell inhibition in vitro

Therapeutic benefits reported for transdermal lisuride in RLS

New data supports the use of pramipexole in restless legs syndrome

Low toxicity, beneficial activity seen with BLP25 liposome vaccine in lung cancer

Tesaglitazar improves lipids, glucose metabolism in insulin-resistant subjects

Recent patents cover new agents for inflammatory disorders

New therapeutics for cancer disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...